Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer.
作者： Masao Hori , Satoshi Inagawa , Jiro Shimazaki , Masayuki Itabashi , Mitsuo Horl
DOI: 10.1016/S0344-0338(00)80081-3
关键词:
摘要: Summary Transactivation of the activation function-1 (AF-1) region estrogen receptor alpha (ER-α) gene is regulated by pathway “cross-talk” from Ras mitogenactivated protein kinase (MAPK). An analysis this system important for solving problem resistance to anti-estrogen agents used in treatment human breast cancer. We investigated ER-α and mutations MAPK-related status 103 cases carcinoma. None showed AF-1 gene. Despite extremely low frequency K - H-Ras codon 12 (2/103 0/103), p21 overexpression was identified 29.1% (30/103), suggesting that almost all we studied not caused point but enhanced expression. Our immunohistochemical with MAPK proteins (Ras p21, ERK-1, JNK-1, p38) had a progressive tendency towards invasive growth, advanced-stage cancer, decreased levels protein. These results suggest activity could be one characteristics advanced cancer it involved transformation into estrogenindependent growth.
elsevier.com
sci-hub.se 参考文章(40)
G. Bunone, P. A. Briand, R. J. Miksicek, D. Picard, Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. The EMBO Journal. ,vol. 15, pp. 2174- 2183 ,(1996) , 10.1002/J.1460-2075.1996.TB00571.X
Christopher Corless, Massimo Loda, Cristina Magi-Galluzzi, Walter Grigioni, Philip J.S. Stork, Youbin Wang, Hong Yao, Rajesh Mishra, Paola Capodieci, Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. American Journal of Pathology. ,vol. 149, pp. 1553- 1564 ,(1996)
Robert I. Nicholson, Keith Griffiths, Douglas W. Wilson, Ian O. Ellis, John Robertson, Christopher W. Elston, Nasser Bouzubar, Roger W. Blamey, Kerry J. Walker, Immunocytochemical Localization of Estrogen Receptor in Human Breast Tissue Cancer Research. ,vol. 48, pp. 6517- 6522 ,(1988)
M. Berry, D. Metzger, P. Chambon, Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. The EMBO Journal. ,vol. 9, pp. 2811- 2818 ,(1990) , 10.1002/J.1460-2075.1990.TB07469.X
A. Wittinghofer, Signal transduction via Ras Biological Chemistry. ,vol. 379, pp. 933- 937 ,(1998)
Anne E. Lykkesfeldt, Per Briand, Søren S. Larsen, Mogens W. Madsen, Birgit E. Reiter, Estrogen Receptor Messenger RNA Splice Variants Are Not Involved in Antiestrogen Resistance in Sublines of MCF-7 Human Breast Cancer Cells Cancer Research. ,vol. 57, pp. 585- 589 ,(1997)
S. R. Ebbs, S. R. D. Johnston, J. Salter, J. Newby, I. E. Smith, G. Saccani-Jotti, M. Coppen, M. Dowsett, Changes in Estrogen Receptor, Progesterone Receptor, and pS2 Expression in Tamoxifen-resistant Human Breast Cancer Cancer Research. ,vol. 55, pp. 3331- 3338 ,(1995)
R. Kedar, T.H. Bourne, W.P. Collins, S. Campbell, T.J. Powles, S. Ashley, D.O. Cosgrove, Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial The Lancet. ,vol. 343, pp. 1318- 1321 ,(1994) , 10.1016/S0140-6736(94)92466-X
Johannes L. Bos, The ras gene family and human carcinogenesis Mutation Research/Reviews in Genetic Toxicology. ,vol. 195, pp. 255- 271 ,(1988) , 10.1016/0165-1110(88)90004-8
Nabil Hagag, Simon Halegoua, Michael Viola, Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21 Nature. ,vol. 319, pp. 680- 682 ,(1986) , 10.1038/319680A0